What podcasts say about Graham Witcomb
Every statement, with the speaker, the exact quote and the moment it was said.
What Graham Witcomb has said on podcasts
35 statements · 19 positive · 15 negative · 1 neutral
Sonic Healthcare is currently undervalued.
“I think that it's undervalued at the moment”
Open the episode · Stock Take: Is the Economic Model Starting to Crack?Listen at 18:34
Sonic’s organic growth is near its highest level in two decades.
“For Sonic, that is kind of almost at the highest that it's been in 20 years.”
Open the episode · Stock Take: Is the Economic Model Starting to Crack?Listen at 19:12
The underlying pathology industry is performing strongly across several markets.
“the underlying pathology industry is doing very, very well”
Open the episode · Stock Take: Is the Economic Model Starting to Crack?Listen at 19:18
Sonic Healthcare may rebound during the current year.
“maybe this is the year Sonic rebounds”
Open the episode · Stock Take: Is the Economic Model Starting to Crack?Listen at 22:16
The number and variety of available pathology tests continue expanding.
“there are more tests than ever and more being invented constantly.”
Open the episode · Stock Take: Is the Economic Model Starting to Crack?Listen at 24:26
Sonic Healthcare would benefit from expanding pathology-test availability.
“Sonic would benefit from that too.”
Open the episode · Stock Take: Is the Economic Model Starting to Crack?Listen at 24:42
Sonic’s efficiency has helped contain healthcare-budget growth.
“Sonic has been a big part of why the, the healthcare budget hasn't exploded even more”
Open the episode · Stock Take: Is the Economic Model Starting to Crack?Listen at 25:51
Sonic Healthcare will not become increasingly efficient.
“Sonic won't become increasingly efficient.”
Open the episode · Stock Take: Is the Economic Model Starting to Crack?Listen at 26:13
Investors should not automatically panic over heavily shorted stocks.
“you shouldn't necessarily freak out when you see stocks that are being overly shorted”
Open the episode · Stock Take: Is the Economic Model Starting to Crack?Listen at 28:01
CSL’s gross-profit segment reporting makes divisions harder to analyze.
“It makes it way more difficult to compare or to figure out which division's doing well”
Open the episode · Stock Take: Misleading MetricsListen at 3:13
Companies changing segment reporting are hiding information.
“there's only one reason that any company changes its reporting like this, which is to hide something”
Open the episode · Stock Take: Misleading MetricsListen at 3:25
Sudden reporting changes may not serve shareholders’ interests.
“There's usually a reason for that change and it's not always in the shareholder's best interest.”
Open the episode · Stock Take: Misleading MetricsListen at 4:55
Excluding CSL’s acquisition amortization obscures real drug-acquisition costs.
“if you exclude those amortization costs from the profit, you're basically saying that there's no cost to buying these startup drugs”
Open the episode · Stock Take: Misleading MetricsListen at 11:11
CSL’s adjusted profit may resemble cash flow but obscures ongoing business costs.
“it's another case of where a company is doing something that might be for, like they could argue this is closer to what the cash flow is for the business. And so shareholders might want to focus on that, but at the same time, it's obscuring what the real costs are that CSL has to endure to keep its business running.”
Open the episode · Stock Take: Misleading MetricsListen at 11:54
EBITDA is useful for comparing companies.
“I don't mind it for comparison purposes. I use it a lot if you're trying to compare different companies”
Open the episode · Stock Take: Misleading MetricsListen at 27:44
Cochlear’s price increases shifted demand toward competitors.
“demand kind of shifted over to them over the past 6 months or a year or so.”
Open the episode · Stock Take: Eight Results That MatterListen at 7:54
Damaged pricing power could undermine Cochlear’s investment case.
“if that is damaged, then it can be Yeah, that, that, that could really ruin its kind of buy case”
Open the episode · Stock Take: Eight Results That MatterListen at 9:29
Successful Horizon 2 yield improvements would give CSL a major competitive advantage.
“if they do, then that's a massive leg up over their competitors.”
Open the episode · Stock Take: Eight Results That MatterListen at 16:28
Horizon 2 could add approximately $500 million in CSL revenue.
“At current kind of sales prices, it'd add probably half a billion of revenue to the company.”
Open the episode · Stock Take: Eight Results That MatterListen at 16:33
Philips will probably re-enter the CPAP market within about a year.
“Philips is probably going to be reentering in the next year or so.”
Open the episode · Stock Take: Eight Results That MatterListen at 24:49
Philips will probably price CPAP products cheaply to rebuild its reputation.
“Philips, which will probably come in and have to start selling cheaply to rebuild its reputation.”
Open the episode · Stock Take: Eight Results That MatterListen at 25:06
Management says GLP-1 users are more likely to continue CPAP therapy.
“management say that people taking those pills are actually more likely to continue therapy with CPAP devices.”
Open the episode · Stock Take: Eight Results That MatterListen at 26:39
Most users discontinue current GLP-1 drugs within six months.
“most people are off them within 6 months.”
Open the episode · Stock Take: Eight Results That MatterListen at 27:21
Current GLP-1 drugs probably will not be transformative long term.
“the current set of GLP-1s are probably not going to be the end. They're not going to be the ones that change the world.”
Open the episode · Stock Take: Eight Results That MatterListen at 27:27
Future oral GLP-1 drugs will probably be more effective or sustainable.
“the next ones, the pills, will probably be better again”
Open the episode · Stock Take: Eight Results That MatterListen at 27:40
AI agents are unlikely to pose a massive threat to REA Group.
“I'm not fully convinced about the AI agents being a massive threat to it”
Open the episode · Stock Take: Eight Results That MatterListen at 33:01
Sonic Healthcare should benefit substantially from AI.
“Sonic should be a huge AI beneficiary because it's all about diagnosis and analysis.”
Open the episode · Stock Take: Eight Results That MatterListen at 36:33
Sonic Healthcare will benefit overall even if GP visits stagnate or decline.
“I think it's going to be a net beneficiary even if GP visits stagnate or do decline.”
Open the episode · Stock Take: Eight Results That MatterListen at 36:53
Government changes could materially affect Sonic Healthcare’s Medicare pricing.
“Sonic's major issue is, uh, Medicare pricing, and that can change with a new government.”
Open the episode · Stock Take: Eight Results That MatterListen at 38:49
Sonic Healthcare is unlikely to deliver outsized returns.
“they're the kind of company you can't ever expect outsized returns from it”
Open the episode · Stock Take: Eight Results That MatterListen at 39:24
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.